Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.

Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, Klein AL

DOI: 10.1067/mje.2001.109505
Published: 2001 Mar
Container: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1067/mje.2001.109505,
  title = {Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.},
  author = {Murray RD and Deitcher SR and Shah A and Jasper SE and Bashir M and Grimm RA and Klein AL},
  year = {2001},
  journal = {Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography},
  doi = {10.1067/mje.2001.109505},
  url = {https://doi.org/10.1067/mje.2001.109505}
}

RIS

TY  - JOUR
TI  - Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.
AU  - Murray RD
AU  - Deitcher SR
AU  - Shah A
AU  - Jasper SE
AU  - Bashir M
AU  - Grimm RA
AU  - Klein AL
PY  - 2001
JO  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
DO  - 10.1067/mje.2001.109505
UR  - https://doi.org/10.1067/mje.2001.109505
ER  -

APA

RD, M., SR, D., A, S., SE, J., M, B., RA, G., & AL, K. (2001). Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. https://doi.org/10.1067/mje.2001.109505

Source records

pubmed · retrieved 2026-09-27T11:01:45.754Z